Foundation Medicine pursues $150M secondary offering; Micro-lens maker Presbia files IPO plans;

@FierceMedDev: Is there such a thing as a 'gentle' colonoscopy device? Invendo thinks so--and brought in $28M for its new tool. Item | Follow @FierceMedDev

@MarkHFierce: Qiagen hit the Chinese market with its next-gen TB test. Competition looms. More | Follow @MarkHFierce

@MichaelGFierce: ICYMI: MedImmune inks licensing deal with Bioasis for brain delivery platform. Story via FierceDrugDelivery | Follow @MichaelGFierce

@EmilyWFierce: Cochlear scored FDA approval for its innovative hearing aid system. Story | Follow @EmilyWFierce

> Cancer diagnostic startup Foundation Medicine ($FMI), which just completed an IPO late last year, plans to raise up to $150 million more in a secondary offering. Story (sub. req).

> Presbia, maker of a micro-lens corneal implant, has filed plans for an IPO worth up to $90 million. Story

> Minnesota's OnPoint Medical Diagnostics filed for Chapter 11 bankruptcy protection and plans to sell its assets to Alliance HealthCare Services in California, a provider of diagnostic-imaging and radiation therapy services. The company had hoped to commercialize technology developed at the Mayo Clinic. Story

> The Netherlands' Bioneedle Technologies Group is developing a tiny biodegradable implant designed to deliver a vaccine and then dissolve as it does its job. Story

> Shanghai-based MicroPort won Chinese regulatory approval for a new, targeted drug-delivery stent for coronary disease. Story

Biotech News

@FierceBiotech: Versartis grabs $126M in an upsized IPO to fund its orphan drug. News | Follow @FierceBiotech

@JohnCFierce: Merck, Endocyte score crucial EMA OK for conditional approval of vintafolide. More | Follow @JohnCFierce

@DamianFierce: EU smiles on Lilly and Boehringer's FDA-rejected diabetes drug. Article | Follow @DamianFierce

@EmilyMFierce: Public-private Japanese partnership invests $15M in neglected diseases. Story | Follow @EmilyMFierce

> Partnerless Aveo is back on the hunt as Biogen returns a cancer drug. Piece

> Novo says Tresiba's down but not out of the blockbuster diabetes race. Read

Pharma News

@FiercePharma: Yesterday's top-read FiercePharmaManufacturing story: NVS CEO predicts generic industry fallout as quality takes center stage. More | Follow @FiercePharma

@TracyStaton: Contrary to popular belief, side-effect reports on new meds hit a steady pace, study finds. Story | Follow @TracyStaton

@EricPFierce: The FDA says it will boost foreign plant inspections 40%, and cut them by same amount in US. News | Follow @EricPFierce

@CarlyHFierce: ICYMI yesterday: Arkansas court boots $1.2B J&J verdict on technical grounds. Article | Follow @CarlyHFierce

> J&J's Velcade cleared by U.K. for first-line myeloma treatment in about-face. Story

> Wockhardt plants cited by Indian regulators. More

> Novo CEO sees improved picture for Tresiba in U.S. market. Piece

Editor's Note: A story on Invendo in Thursday's FierceMedicalDevices misstated the location of Garden City. It is in New York state.

Suggested Articles

The FDA has cleared its first fully disposable duodenoscope, following years of reports of infections being transmitted between patients.

OR-focused AI provider Caresyntax has garnered $45.6 million in new funding and picked up a data analytics firm to broaden its footprint.

A study of Foundation Medicine’s FoundationOne liquid biopsy test found it was able to predict the risk that a person’s breast cancer would return.